sox17a-b Antibody

What are SOX17a and SOX17b and how do they differ functionally?

SOX17a and SOX17b are paralogs of the SOX17 transcription factor found primarily in Xenopus. These paralogs share conserved N-terminal regions but differ in their C-terminal domains. In Xenopus, there are three paralogs that function in endoderm specification and development . These paralogs have overlapping but distinct functions in developmental contexts, with all three requiring knockdown to achieve complete loss of function phenotypes. The functional specificity appears to be determined by interactions with lineage-specific transcription factors, as Sox17 gains DNA-binding specificity through protein-protein interactions with various partners .

What epitopes are commonly targeted by SOX17 antibodies?

Most commercial SOX17 antibodies target one of three main epitope regions:

• The region corresponding to amino acids 177-414 of human SOX17 (Asp177-Val414), which represents a significant portion of the protein and is used for multiple commercial antibodies

• N-terminal regions that may be conserved across SOX17 paralogs, providing broader reactivity across variants

• C-terminal regions that may confer specificity to particular SOX17 variants, as demonstrated in antibodies generated against Sox17a C-terminal and Sox17b C-terminal regions

The selection of these epitopes is based on conservation across species, surface accessibility in the native protein, and uniqueness compared to other SOX family members. Antibodies targeting different epitopes may exhibit varying performance across applications, with SOX17b C-terminal antibodies demonstrating superior performance in ChIP applications in some studies .

What is the expected molecular weight of SOX17 in Western blotting?

While the theoretical molecular weight of SOX17 is reported as approximately 44.1 kDa , the observed molecular weight in Western blots typically ranges from 55-59 kDa:

This discrepancy between theoretical and observed molecular weights is likely due to post-translational modifications, particularly phosphorylation or glycosylation, which are common in transcription factors. Researchers should anticipate this higher molecular weight when interpreting Western blot results and should include appropriate positive controls to confirm band identity .

How can I validate the specificity of a SOX17 antibody?

A comprehensive validation strategy for SOX17 antibodies should include multiple approaches:

• Genetic depletion controls: Compare antibody signals between wild-type samples and those where SOX17 has been depleted via siRNA, CRISPR, or morpholinos. In ChIP experiments, Sox17-MO embryos showed binding reduced to near background levels at 9 of 10 loci tested, confirming robust knockdown and antibody specificity .

• Peptide competition assays: Add increasing amounts of the immunizing peptide to reduce the antibody signal in a dose-dependent manner. For example, "Addition of the Sox17b C-terminal peptide reduced the ChIP signal in a dose-dependent manner indicating specific binding" .

• Cellular differentiation models: Test antibody in undifferentiated versus endoderm-differentiated stem cells where SOX17 is known to be strongly upregulated. Multiple studies show clear detection of SOX17 in differentiated but not undifferentiated stem cells .

• Multi-antibody concordance: Use antibodies raised against different epitopes of SOX17 and confirm similar binding patterns. This approach can identify epitope-specific artifacts versus true SOX17 signals .

• Cross-species validation: When possible, test reactivity in multiple species to confirm evolutionary conservation of the signal pattern .

What are the recommended protocols for SOX17 ChIP-seq experiments?

Based on successful published protocols, an optimized SOX17 ChIP-seq workflow includes:

• Fixation: Cross-link protein-DNA complexes using formaldehyde (typically 1%) in intact cells or tissues.

• Chromatin preparation: Lyse cells, isolate nuclei, and sonicate chromatin to obtain fragments of 200-500 bp.

• Immunoprecipitation: Use 5 μg of anti-SOX17 antibody per 5×10^6 cells. The Goat Anti-Human SOX17 Antigen Affinity-purified Polyclonal Antibody (AF1924) has been successfully used in multiple studies .

• Capture method options:

  • Biotinylated secondary antibodies with streptavidin ferrofluid (MagCellect Streptavidin Ferrofluid)

  • Protein A/G beads (standard approach, not explicitly mentioned in the search results)

• Washing and elution: Perform stringent washing followed by elution of DNA-protein complexes.

• Reversal of cross-links and DNA purification: Heat samples to reverse formaldehyde cross-links, digest proteins with proteinase K, and purify DNA.

• Library preparation and sequencing: Prepare sequencing libraries following standard NGS protocols.

• Data analysis: Identify statistically significant SOX17-bound regions (e.g., using IDR with p<0.05) . Enhancer annotation can be performed using HOMER to associate peaks with the nearest transcription start sites .

Preliminary ChIP-qPCR comparing different SOX17 antibodies can identify the most efficient antibody for ChIP-seq. In one study, "the Sox17bC-terminal antibody was more efficient and was used for ChIP-seq" .

How can I optimize SOX17 immunostaining for different cell types?

Optimizing SOX17 immunostaining requires careful attention to several parameters:

• Fixation methods:

  • For immunocytochemistry, use fixation buffer followed by permeabilization with either 100% ice-cold methanol or 0.5% Triton-X

  • Avoid fixation and permeabilization with 100% ice-cold methanol alone, as this can mask the epitope

• Antigen retrieval for tissue sections:

  • For immunohistochemistry, perform antigen retrieval with either Tris-EDTA (10 mM Tris, 1 mM EDTA, 0.05% Tween-20, pH 9.0) or Sodium Citrate buffer

• Antibody concentrations:

  • For immunocytochemistry: 5-15 μg/mL (typically 10 μg/mL)

  • For immunohistochemistry: 1-10 μg/mL

• Incubation conditions:

  • Room temperature incubation for ~3 hours has been successful in multiple protocols

• Detection systems:

  • Fluorescent secondary antibodies such as NorthernLights 557-conjugated anti-IgG antibodies provide good signal-to-noise ratio

  • Counterstain with DAPI to confirm the expected nuclear localization of SOX17

For optimal results in endoderm differentiation studies, include co-staining with other endoderm markers like FOXA2 to confirm proper differentiation status and provide internal controls for antibody performance .

How does SOX17 interact with Wnt/β-catenin signaling and how can antibodies detect these interactions?

SOX17 exhibits complex interactions with Wnt/β-catenin signaling that can be studied using antibody-based approaches:

• Genomic co-occupancy: "Over a third of all Bcat and Sox17 genomic binding in the gastrula occur at the same CRMs [cis-regulatory modules]" , indicating extensive cooperation at the chromatin level. This can be studied using parallel or sequential ChIP experiments with SOX17 and β-catenin antibodies.

• Context-dependent regulation: SOX17 can either suppress β-catenin-Tcf mediated transcription in some contexts or synergistically activate enhancers with β-catenin independently of Tcfs in others . This dual regulatory capacity can be investigated using reporter assays coupled with immunoprecipitation studies.

• DNA binding competition: SOX and TCF factors bind similar DNA motifs (SOX: 5'-(A/T)(A/T)CAA(A/T)3' vs TCF: 5'-T(A/T)(A/T)CAAG 3') , suggesting potential competition for binding sites that can be studied through mutational analysis and ChIP.

To investigate these interactions, researchers can employ:

• ChIP-seq with SOX17 and β-catenin antibodies to identify sites of co-occupancy

• Sequential ChIP (Re-ChIP) to confirm simultaneous binding

• Co-immunoprecipitation to detect physical interactions

• Proximity ligation assays to visualize protein-protein interactions in situ

These approaches have established SOX17 as a "tissue-specific modifier of Wnt responses" and point to "a novel paradigm where genomic specificity of Wnt/β-catenin" signaling is regulated by lineage-specific factors like SOX17 .

How can SOX17 antibodies be used to study its role in vascular development and disease?

SOX17 plays critical roles in vascular development and pulmonary arterial hypertension (PAH), which can be investigated using SOX17 antibodies:

• Genetic association studies: "Common PAH risk variants upstream of the SOX17 promoter reduce endothelial SOX17 expression, at least in part, through differential binding of HOXA5 and ROR-α" . SOX17 antibodies can be used in conjunction with these transcription factor antibodies to study regulatory mechanisms.

• Functional consequences: "SOX17 silencing in hPAECs resulted in increased apoptosis, proliferation, and disturbance of barrier function" . These phenotypes can be monitored using SOX17 antibodies in both normal and disease states.

• Vascular cell identification: SOX17 antibodies can identify specific vascular endothelial cell populations, as demonstrated in kidney organoid studies where "IF staining of D29 kidney organoid for SOX17 and CD31, markers of endothelial cells" was performed .

• Molecular mechanisms: "Analysis of the hPAEC transcriptomes revealed alteration of PAH-relevant pathways on SOX17 silencing, including extracellular matrix regulation" . ChIP studies using SOX17 antibodies can identify direct transcriptional targets in vascular cells.

• Therapeutic screening: Connectivity map analysis identified "compounds that reversed the SOX17-dysfunction transcriptomic signatures in hPAECs" . SOX17 antibodies can help validate these compounds' effects on SOX17 expression and function.

For these applications, researchers should select antibodies validated in vascular endothelial cells and incorporate appropriate controls to distinguish SOX17 from other SOX family members expressed in the vasculature.

What approaches can resolve inconsistent SOX17 antibody staining patterns?

When facing variability in SOX17 antibody staining, consider these systematic troubleshooting approaches:

• Fixation optimization: For ICC, use fixation buffer followed by permeabilization with either 100% ice-cold methanol or 0.5% Triton-X. Importantly, fixation and permeabilization with 100% ice-cold methanol alone is not recommended as it may mask epitopes .

• Antigen retrieval methods: For IHC, test multiple retrieval methods including Tris-EDTA (10 mM Tris, 1 mM EDTA, 0.05% Tween-20, pH 9.0) and Sodium Citrate buffer to maximize epitope accessibility .

• Antibody validation with knockdown controls: Perform siRNA experiments targeting SOX17 to confirm antibody specificity. Studies have used "silencer select siRNA (ThermoFisher) targeting SOX17 (No. s34626)" and appropriate controls .

• Epitope accessibility assessment: Different antibodies recognize distinct epitopes that may be differentially accessible in various experimental conditions. For example, N-terminal antibodies may perform differently than C-terminal antibodies depending on protein interactions .

• Positive control inclusion: Include samples known to express high levels of SOX17, such as "endoderm differentiated BG01V human embryonic stem cells" which consistently show strong SOX17 positivity .

• Differentiation stage consideration: For stem cell studies, the precise stage of differentiation dramatically affects SOX17 expression. Documentation shows that "Activin-A levels during Day 0–1 modulate cardiomyocyte vs. definitive endoderm differentiation" with corresponding changes in SOX17 expression patterns .

• Cross-antibody validation: When possible, verify staining patterns with multiple antibodies targeting different SOX17 epitopes to distinguish true signal from artifacts.

How can SOX17 antibodies be used to study endoderm specification in organoid systems?

SOX17 antibodies are valuable tools for investigating endoderm development in organoid systems:

• Lineage tracing: SOX17 is a critical marker for defining endodermal contributions to organoids. In kidney organoids, "IF staining of D29 kidney organoid for SOX17 and CD31, markers of endothelial cells" helped characterize vascular components .

• Differentiation protocol optimization: SOX17 antibodies can assess differentiation efficiency and purity. Immunostaining data shows that "differentiation of hESCs into definitive endoderm cells by Activin A with CHIR99021" can be monitored through SOX17 expression, with optimal conditions producing robust SOX17+/FOXA2+ populations .

• Organoid patterning analysis: Co-staining with SOX17 and other lineage markers helps map organoid spatial organization. For example, quantitative immunofluorescence can assess "concordant expression of developmental programs across organoids from human iPSC lines" .

• Genetic manipulation validation: When modifying SOX17 levels in organoids, antibodies confirm the effectiveness of genetic interventions. Data shows clear distinction between "lysates of BG01V human embryonic stem cells untreated (-) or endoderm differentiated (+)" when probed for SOX17 .

• Cross-platform validation: SOX17 antibodies can verify findings across different analysis platforms. Published work demonstrates consistent results between "western blot shows lysates of BG01V human embryonic stem cells" and immunofluorescence of the same cell types .

For optimal organoid analysis, researchers should employ Z-stack confocal imaging to capture SOX17 expression throughout three-dimensional structures, and quantitative image analysis to measure expression gradients across different organoid regions.

What role does SOX17 play in chromatin remodeling and how can this be studied with antibodies?

SOX17's function in chromatin remodeling can be investigated using antibody-based approaches:

• Pioneer factor activity: SOX17 may function as a pioneer factor that can access closed chromatin. ChIP-seq analysis shows that "most of the Sox17-bound genomic loci were also bound by Ep300, indicative of active enhancers" , suggesting SOX17 may recruit chromatin modifiers.

• Co-localization with chromatin modifiers: Dual immunofluorescence or proximity ligation assays can identify interactions between SOX17 and chromatin remodeling complexes in situ.

• Enhancer activation: SOX17 binding is associated with enhancer activation. ChIP-qPCR validation experiments demonstrate that SOX17 antibodies can successfully pull down regulatory regions such as the "p21 promoter" in chromatin immunoprecipitation assays .

• Genomic co-occupancy: SOX17 collaborates with other factors at specific genomic loci. Research shows that "Sox17-bound loci were also enriched for Tbx, Gata, Fox and homeodomain motifs" , indicating potential cooperative chromatin remodeling.

• Context-dependent activity: SOX17 can act as either an activator or repressor depending on genomic context. Data reveals that "enhancers that were negatively regulated by Sox17 were enriched for Tbx and Oct motifs whereas enhancers activated by Sox17 were enriched for homeodomain motifs" .

These studies require high-quality SOX17 antibodies validated for chromatin immunoprecipitation, as well as appropriate controls to distinguish direct SOX17 effects from secondary consequences of its transcriptional activity.

How can SOX17 antibodies contribute to our understanding of human developmental disorders?

SOX17 antibodies are valuable tools for investigating developmental disorders involving endoderm derivatives and vascular systems:

• Genetic variant functional validation: For variants identified in clinical studies, SOX17 antibodies can assess their impact on protein expression and localization. Research shows that "SOX17 enhancer variants disrupt transcription factor binding" , and antibodies can determine how these variants affect SOX17 protein levels.

• Disease mechanism investigations: In pulmonary arterial hypertension, "SOX17 enhancer knockout in mice reduced lung SOX17 expression, resulting in more severe pulmonary vascular leak and hypoxia-induced pulmonary hypertension" . Antibodies can track these pathological changes at the protein level.

• Cell fate mapping in development: SOX17 antibodies help identify aberrant lineage specification in developmental disorders. Studies demonstrate that in proper development, "SOX17 is detected in immersion fixed endoderm differentiated BG01V human embryonic stem cells" , providing a baseline for comparison with pathological samples.

• Therapeutic response monitoring: When testing interventions aimed at modulating SOX17 expression, antibodies provide essential validation of target engagement. Research has identified "compounds that reversed the SOX17-dysfunction transcriptomic signatures" , and antibodies can confirm their effects on SOX17 protein levels.

• Biomarker development: SOX17 expression patterns may serve as diagnostic or prognostic biomarkers. "Plasma proteomic differences in patients with differing SOX17 variant genotypes" suggest downstream effects that can be characterized using SOX17 antibodies in conjunction with proteomics.

For these applications, researchers should select antibodies with demonstrated specificity in the relevant tissue context and incorporate appropriate genetic controls to validate findings in disease models.